Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib impact on [18F]ciprofloxacin uptake in bone metastases of hormone-refractory prostate cancer
2006-001539-23Phase 4Terminated
- Sponsor
- Department of Clinical Pharmacology
- Start
- May 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of imatinib in prostate cancer (PCa) and bone metastases, sponsored by Department of Clinical Pharmacology. Primary endpoint: Total [18F]ciprofloxacin concentrations in HRPC bone metastases (AUCPET 0–2 h). Started May 2006; status: terminated.
02
Drugs
03
Conditions
prostate cancer (PCa)bone metastases
Beyond the preview
Go deeper on 2006-001539-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001539-23.